SMS Pharmaceuticals Management
Management criteria checks 3/4
SMS Pharmaceuticals' CEO is Ramesh Potluri, appointed in Aug 1990, has a tenure of 33.75 years. total yearly compensation is ₹30.75M, comprised of 97.6% salary and 2.4% bonuses, including company stock and options. directly owns 36.22% of the company’s shares, worth ₹6.26B. The average tenure of the management team and the board of directors is 5 years and 7.9 years respectively.
Key information
Ramesh Potluri
Chief executive officer
₹30.7m
Total compensation
| CEO salary percentage | 97.6% |
| CEO tenure | 33.8yrs |
| CEO ownership | 36.2% |
| Management average tenure | 5yrs |
| Board average tenure | 7.9yrs |
Recent management updates
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 110% And Shareholders Are Boasting About It
Oct 28What Kind Of Shareholders Hold The Majority In SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Shares?
Oct 08Are Dividend Investors Getting More Than They Bargained For With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Dividend?
Sep 17SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Aug 26SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Could Signal Some Risk
Aug 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Business Is Trailing The Market But Its Shares Aren't
Aug 08SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Looks Just Right
Jul 25SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Price Matching Investor Opinion
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Compensation vs Market: Ramesh's total compensation ($USD368.33K) is above average for companies of similar size in the Indian market ($USD185.58K).
Compensation vs Earnings: Ramesh's compensation has been consistent with company performance over the past year.
CEO
Ramesh Potluri (65 yo)
33.8yrs
Tenure
₹30,745,000
Compensation
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 33.8yrs | ₹30.75m | 36.22% ₹ 6.3b | |
| Chief Financial Officer | 6.7yrs | ₹2.30m | no data | |
| Company Secretary & Compliance Officer | 2.3yrs | ₹1.49m | no data | |
| Executive Director | 3.3yrs | ₹6.69m | 15.74% ₹ 2.7b | |
| Assistant General Manager of HR and Legal | no data | no data | no data | |
| Head of HRD and General Manager of Purchases | no data | no data | no data |
5.0yrs
Average Tenure
60yo
Average Age
Experienced Management: SMSPHARMA's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 33.8yrs | ₹30.75m | 36.22% ₹ 6.3b | |
| Executive Director | 3.9yrs | ₹6.69m | 15.74% ₹ 2.7b | |
| Non-Executive & Independent Director | 9.8yrs | ₹100.00k | 0.10% ₹ 17.4m | |
| Non-Executive & Independent Director | 9.8yrs | ₹310.00k | no data | |
| Non-Executive & Independent Director | 4.8yrs | ₹100.00k | no data | |
| Non-Executive & Independent Director | 6yrs | ₹330.00k | 0.035% ₹ 6.1m |
7.9yrs
Average Tenure
60.5yo
Average Age
Experienced Board: SMSPHARMA's board of directors are considered experienced (7.9 years average tenure).